Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users

被引:47
作者
Alexander, CS
Dong, W
Schechter, MT
O'Shaughnessy, MV
Strathdee, SA
Mo, T
Montaner, JSG
Harrigan, PR
机构
[1] St Pauls Hosp, BC Ctr Excellence HIV AIDS, Res Labs, Vancouver, BC V6Z 1Y6, Canada
[2] Univ British Columbia, Fac Med, Dept Hlth Care & Epidemiol, Vancouver, BC, Canada
[3] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada
关键词
injecting drug use; HIV; antiretrovirals; resistance;
D O I
10.1097/00002030-199905280-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: This study examined the frequency of transmission of drug resistant HIV in the population of injecting drug users (IDU) in Vancouver, Canada during a period of particularly high virus transmission. Design: All subjects enrolled in the Vancouver Injection Drug Users Study who seroconverted from HIV negative to positive status (n = 61) between December 1996 and February 1998 were eligible for analysis. The first seropositive sample from 57 individuals with plasma samples available was analyzed for resistance to antiretroviral agents by population based sequencing of the HIV protease and reverse transcriptase genes. Methods: Plasma viral RNA was extracted and the viral reverse transcriptase and protease regions were amplified by nested reverse transcription-PCR. The presence of mutations associated with antiretroviral drug resistance was assessed by automated sequence analysis. Results: Protease and reverse transcriptase sequences were successfully obtained from the 57 recent seroconverters. No cases of transmission of variants associated with significant resistance to protease inhibitors or nucleoside and non-nucleosides reverse transcriptase inhibitors were detected. Conclusion: The frequency of transmission of drug resistant HIV amongst these recently infected IDU is extremely low, with no protease or reverse transcriptase inhibitor resistant strains detected soon after seroconversion. The data provide no rationale for withholding treatment from this already marginalized population. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:981 / 985
页数:5
相关论文
共 39 条
[1]  
[Anonymous], [No title captured]
[2]  
BANGSBERG D, 1997, JAMA-J AM MED ASSOC, V278, P1962
[3]  
BRAUN P, 1998, 12 WORLD AIDS C GEN
[4]  
*CDC, 1997, MMWR-MORBID MORTAL W, V46, P65
[5]   Self-reported antiretroviral therapy in injection drug users [J].
Celentano, DD ;
Vlahov, D ;
Cohn, S ;
Shadle, VM ;
Obasanjo, O ;
Moore, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06) :544-546
[6]   HETEROSEXUAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS ASSOCIATED WITH ZIDOVUDINE RESISTANCE [J].
CONLON, CP ;
KLENERMAN, P ;
EDWARDS, A ;
LARDER, BA ;
PHILLIPS, RE .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02) :411-415
[7]  
CONWAY B, 1997, INT WORKSH HIV DRUG
[8]   First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands [J].
deRonde, A ;
Schuurman, R ;
Goudsmit, J ;
vandenHoek, A ;
Boucher, C .
AIDS, 1996, 10 (02) :231-232
[9]   INTERNATIONAL EPIDEMIOLOGY OF HIV AND AIDS AMONG INJECTING DRUG-USERS [J].
DESJARLAIS, DC ;
FRIEDMAN, SR ;
CHOOPANYA, K ;
VANICHSENI, S ;
WARD, TP .
AIDS, 1992, 6 (10) :1053-1068
[10]   BRIEF REPORT - PRIMARY INFECTION WITH ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
ERICE, A ;
MAYERS, DL ;
STRIKE, DG ;
SANNERUD, KJ ;
MCCUTCHAN, FE ;
HENRY, K ;
BALFOUR, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (16) :1163-1165